DMPK Challenges and Strategies for Developing Oligonucleotide Drugs

Oligonucleotides comprise a rapidly growing class of therapeutics. However, due to their novelty, complexity and limited regulatory guidance, oligonucleotides have more technical challenges and unknown consequences for drug developers compared to more conventional drugs. As such, oligonucleotides require pharmacokinetic evaluation systems that differ from traditional assays in significant ways. We will share our strategies to tackle these DMPK challenges and accelerate oligonucleotide drug development. Challenges will be further broken down into three categories: ADME, metabolite identification and profiling, and bioanalysis. Attendees can also expect to learn about current trends in developing oligonucleotide drugs and strategies and solutions to tackle these DMPK challenges for oligonucleotides.

Join this webinar to learn

• The current trend of developing oligonucleotide drugs

• The DMPK challenges and strategies for developing oligonucleotide drugs

• ADME study requirements for oligonucleotide drugs

• Metabolite identification and profiling of oligonucleotide drugs

• Familiarity with flexible and comprehensive platforms for bioanalysis solutions